ABSTRACT
Amyotrophic Lateral Sclerosis (ALS) is a multisystemic neurodegenerative disorder, with accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN) degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell lines with genetic knockdown of genes related to familial ALS, such as TARDBP (TDP-43) and FUS. We found a functional impairment of myogenesis that parallels defects of glucose oxidation in ALS muscle cells. We identified FOXO1 transcription factor as a key mediator of these metabolic and functional features in ALS muscle, via gene expression profiling and biochemical surveys in TDP-43 and FUS silenced muscle progenitors. Strikingly, inhibition of FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary ALS myoblasts. In addition, specific in vivo conditional knockdown of TDP-43 or FUS orthologs (TBPH or caz) in Drosophila muscle precursor cells resulted in decreased innervation and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially corrected by foxo inhibition, bolstering the potential pharmacological management of muscle intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle dysfunction in ALS, which can be modulated by targeting FOXO factors, paving the way for novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue.
Competing Interest Statement
SD is a named inventor on patents related to neurological disorders. MZuf, ALM, GG, FGB and SAM are co-inventors of patent PCT/EP2021/064274 and therefore entitled to a share of royalties. MZuf, LB, ALM, GGL, FGB and SAM also have ownership in Miaker Developments S.L., which is the licensee of that patent related to the research being reported. The terms of this arrangement have been reviewed and approved by the University of the Basque Country and Biogipuzkoa Health Research Institute/BIOEF (representing the Basque public administration), as co-owners of the patent.
Funding Statement
This research was supported by the Biodonostia Health Research Institute (Biodonostia HRI) and CIBER (Consorcio Centro de Investigacion Biomedica en Red- (CB06/05/1126, Group 609), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion and Union Europea) European Regional Development Fund. This work was funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (projects P18/01066, PI19/00175, PI21/00153, PI22/00433); by CIBERNED (CIBER de Enfermedades Neurodegenerativas, project PI2020/08-1); by the Department of Education of the Basque Country through the IKUR strategy (NEURODEGENPROT); Diputacion Foral de Gipuzkoa (projects 2020-CIEN-000057-01, 2021-CIEN-000020-01); by EiTB Maratoia (project BIO17/ND/023/BD); and by Osasun Saila, Eusko Jaurlaritzako (projects 2015111122, 2017222027, 2018111042, 2019222020, 2020111032, 2020333043, 2021333050). MZuf, OP-M, MG-A, AJ, AE, JO and UF-P were supported by the Department of Education of the Basque Country (PhD fellowships PRE_2015_1_0023, PRE_2019_1_0339, PRE_2020_1_0122, PRE_2020_1_0191, PRE_2020_1_0119, PRE_2018_1_0095, PRE_2018_1_0253); MM-O by Basque Country University (UPV/EHU) fellowship (PIF18/317); LB by the Spanish National Plan for Scientific and Technical Research and Innovation-Ramon y Cajal- (RYC2018-024397-I) and IKERBASQUE (RF/2019/001) research programs; GG by Juan de la Cierva-Incorporacion (ISCIII, IJC2019-039965-I) and IKERBASQUE (RF/2023/010) research programs; FG-B by Roche Stop Fuga de cerebros (BIO19/ROCHE/017/BD) and IKERBASQUE (PP/2022/003) research programs; and SA-M by Gipuzkoa Fellow of Talent Attraction and Retention (2019-FELL-000010-01, 2020-FELL-000016-02-01, 2021-FELL-000013-02-01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Clinical Research Ethics Committees of the Basque Country and Donostia University Hospital (codes: ALM-EMP- 2015-01, PI2016075, PI2019198) (Spain). Written informed consent was obtained from all the subjects included in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE227573
